Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17592150 | 1.00 | GNAI3 (0.31) | GNAI3GNAO1GNAI1SMYD3NPC1 | |
| SCHEMBL600825 | 1.00 | GNAI3 (0.31) | GNAI3GNAO1GNAI1SMYD3NPC1 | |
| SCHEMBL684437 | 0.87 | — | — | |
| SCHEMBL20337353 | 0.87 | EPHX2 (0.35) | — | |
| SCHEMBL13179149 | 0.87 | NPC1 (0.36) | NPC1 | |
| SCHEMBL8598298 | 0.86 | GNAI3 (0.37) | GNAI3GNAO1GNAI1SMYD3SPHK1 | |
| SCHEMBL19667809 | 0.86 | GNAI3 (0.37) | GNAI3GNAO1GNAI1SMYD3SPHK1 | |
| Hydrochloric Acid SCHEMBL2965976 | 0.85 | GNAI3 (0.40) | GNAI3GNAO1GNAI1SMYD3SPHK1 | |
| Hydrochloric Acid SCHEMBL2965979 | 0.85 | GNAI3 (0.40) | GNAI3GNAO1GNAI1SMYD3SPHK1 | |
| SCHEMBL17730281 | 0.85 | EPHX2 (0.41) | GNAI3GNAO1GNAI1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | claimed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-11453675-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-09-27 | — | — | US | disclosed |
| CN-109311887-B | Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions | BIAL研发投资股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-7138397-B2 | Nitrogenous 5-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1076649-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055679-A1 | ISOQUINOLINE COMPOUND MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USING SAME | TREGA BIOSCIENCES, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5852023-A | Cyclohexylamino and cycloalkoxy nitrogen heterocycles, processes for their preparation, and their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0817774-A1 | CYCLOHEXYLAMINO AND CYCLOHEXYLALKOXY NITROGEN HETEROCYCLES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS AND FUNGICIDES | Hoechst Schering AgrEvo GmbH (DE) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030345-A1 | CYCLOHEXYLAMINO AND CYCLOHEXYLALKOXY NITROGEN HETEROCYCLES, METHODS OF PREPARING THEM AND THEIR USE AS PEST-CONTROL AGENTS AND FUNGICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | GNAI3 259/4885GNAO1 51/4885GNAI1 127/4885 |
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | GNAI3 1217/4885GNAO1 84/4885GNAI1 520/4885 |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, PARK7, GAA | GNAI3 311/4885GNAO1 53/4885GNAI1 146/4885 |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | GNAI3 3186/4885GNAO1 702/4885GNAI1 2776/4885 |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | GNAI3 467/4885GNAO1 49/4885GNAI1 252/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | GNAI3 3191/4885GNAO1 788/4885GNAI1 3036/4885 |
| US-11453675-B2 | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | GBA1, GAA, GBA2 | GNAI3 213/4885GNAO1 79/4885GNAI1 102/4885 |
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | GNAI3 2038/4885GNAO1 1253/4885GNAI1 2101/4885 |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | GNAI3 75/4885GNAO1 391/4885GNAI1 37/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GNAI3 80/4885GNAO1 379/4885GNAI1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.